• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Baxter stock moves up on delayed Q4 results

Baxter stock moves up on delayed Q4 results

March 17, 2020 By Sean Whooley

BaxterBaxter (NYSE:BAX) shares ticked up today on fourth-quarter results that topped the consensus forecast after delayed reporting because of an internal probe.

Shares of BAX were up 10.4% at $78.98 in early-afternoon trading today.

The Deerfield, Ill.–based company posted losses of -$19 million, or -5¢ per share, on sales of $3.04 billion for the three months ended Dec. 31, 2019, dipping below zero on its bottom line after profits of $311 million in this quarter last year, despite sales growth of 7.3%.

Adjusted to exclude one-time items, earnings per share were 97¢, 9¢ ahead of Wall Street, where analysts were looking for sales of $2.98 billion.

“Our sales and earnings performance in 2019 demonstrate the momentum and underlying strength of our ongoing transformation,” Baxter chairman, president & CEO José Almeida said in a news release. “We are driving growth across our global businesses and regions, fueled by innovation and commercial execution that position us for sustained success.

“Our focus remains on advancing our mission for patients and accelerating value for all stakeholders. We look forward to building on our progress in quarters to come.”

The delay in Baxter’s effort to report its financial results was due to an internal probe into its foreign exchange trading practices launched in October 2019. The investigation concluded last month and uncovered that Baxter’s income for the past four years may have been overstated by $276 million.

“Our investigation of this matter as it relates to its financial impacts is now complete,” Almeida said. “The relevant foreign exchange gains and losses were non-operational in nature, and our core operational performance across this period continues to demonstrate the strength and trajectory of our ongoing transformation, fueled by revitalized innovation, increased efficiency and the dedication of our 50,000 employees worldwide.”

Baxter said it is not giving any guidance for full-year 2020 right now, given the degree of uncertainty surrounding the impact of the coronavirus pandemic. The company said it expects to have an update when it announces first-quarter earnings on April 30.

The company added that it has experienced limited financial impact due to coronavirus so far, but it is not in a position to estimate the potential impact down the road, given the dynamic nature of the situation.

Filed Under: Business/Financial News, Featured, MassDevice Earnings Roundup, Wall Street Beat Tagged With: Baxter

More recent news

  • Aurora Spine begins first procedures with Aero lumbar fusion system
  • Caranx Medical surgical robot TaviPilot AI software wins FDA clearance
  • InspireMD launches carotid stent in U.S. after FDA approval
  • Neuros Medical raises $56M Series D to support nerve stim tech
  • CorWave reports first-in-human LVAD implant

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy